Omic-technologies (genomics, transcriptomics, proteomics and metabolomics) have become more important in current medical science. Among them, it is metabolomics that most accurately reflects the minor changes in body functioning, as it focuses on metabolome – the group of the metabolism products, both intermediate and end. Therefore, metabolomics is actively engaged in fundamental and clinical studies and search for potential biomarkers. The biomarker could be used in diagnostics, management and stratification of the patients, as well as in prognosing the outcomes. The good example is gynecology, since many gynecological diseases lack effective biomarkers. In the current review, we aimed to summarize the results of the studies, devoted to the search of potential metabolomic biomarkers for the most common gynecological diseases.

Original languageEnglish
Pages (from-to)3611-3622
Number of pages12
JournalCurrent Medicinal Chemistry
Volume27
Issue number22
DOIs
StatePublished - 2020

    Research areas

  • Biomarkers, Endometriosis, Gynecology, Leiomyoma, Metabolomics, Ovarian neoplasms, Polycystic ovary syndrome, Uterine cervical neoplasms

    Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

ID: 87784368